Contraindicated (1)bortezomib will raise the stage or outcome of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may possibly maximize mavacamten systemic publicity, leading to heart failure resulting from systolic dysfunction. Treatment causes peripheral neuropathy (predominantly sensory); nevertheless, instances of se... https://curcumenol66543.csublogs.com/32682026/the-best-side-of-2